BACKGROUND: Human African trypanosomiasis is fatal without treatment. The long post-treatment follow-up (24 months) required to assess cure complicates patient management and is a major obstacle in the development of new therapies.
BACKGROUND: In 2005, the Democratic Republic of Congo (DRC) adopted artesunate and amodiaquine (ASAQ) as first-line anti-malarial treatment.
BACKGROUND: In 2008, Africa accounted for 94% of the cholera cases reported worldwide.
BACKGROUND: Data on efficacy of artemisinin-based combination therapy (ACT) to treat Plasmodium falciparum during pregnancy in sub-Saharan Africa is scarce.
BACKGROUND: Data from the largest randomized, controlled trial for the treatment of children hospitalized with severe malaria were used to identify such predictors of a poor outcome from severe malaria.
Improved laboratory diagnosis is critical to reduce the burden of malaria in pregnancy.
In Africa, although emergence of multidrug-resistant (MDR) tuberculosis (TB) represents a serious threat in countries severely affected by the HIV epidemic, most countries lack drug-resistant TB data.
Measles epidemics in West Africa cause a significant proportion of vaccine-preventable childhood mortality.
Providing abandoned children the necessary medical and psychological care as possible after their institutionalization may minimize developmental delays.
Despite impressive gains in measles control globally, measles epidemics continue to occur in countries with insufficient vaccination coverage.
